Maria Gonzales
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Maria Gonzales has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
Alexander Christopher Jonathan Van Akkooi
Netherlands Cancer Institute, Amsterdam, Netherlands
1 shared publication- Alexander Maxwell Menzies
Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia
1 shared publication - Anna Ong-Lim
College of Medicine - Philippine General Hospital, University of the Philippines, Manila, Philippines
1 shared publication - Christian U. Blank
Leiden University Medical Center, Leiden, The Netherlands
1 shared publication - Christoph Hoeller
Department of Dermatology, Medical University of Vienna, Vienna, Austria
1 shared publication - Elisa A. Rozeman
Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands
1 shared publication
Latest Publications
- Open Access
- 9 September 2022
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 18 (6) , 2110759
Invasive meningococcal disease in Malaysia, Philippines, Thailand, and Vietnam: An Asia-Pacific expert group perspective on current epidemiology and vaccination policies
Invasive meningococcal disease (IMD) imposes a significant burden on the global community due to its high case fatality rate (4-20%) and the risk of long-term sequelae for one in five survivors. An expert group meeting was held to discuss the epidemiology of IMD and immunization policies in Malaysia, Philippines, Thailand, and Vietnam. Most of these countries do not include meningococcal immunization in their routine vaccination programs, except for high-risk groups such as immunocompromised people and pilgrims. It is difficult to estimate the epidemiology of IMD in the highly diverse Asia-Pacific region, but available evidence indicate serogroup B is increasingly dominant. Disease surveillance systems differ by country. IMD is not a notifiable disease in some of them. Without an adequate surveillance system in the region, the risk and the burden of IMD might well be underestimated. With the availability of new combined meningococcal vaccines and the World Health Organization roadmap to defeat bacterial meningitis by 2030, a better understanding of the epidemiology of IMD in the Asia-Pacific region is needed.
- 9 September 2022
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 18 (6) , 2110759
Open AccessInvasive meningococcal disease in Malaysia, Philippines, Thailand, and Vietnam: An Asia-Pacific expert group perspective on current epidemiology and vaccination policies
Invasive meningococcal disease (IMD) imposes a significant burden on the global community due to its high case fatality rate (4-20%) and the risk of long-term sequelae for one in five survivors. An expert group meeting was held to discuss the epidemiology of IMD and immunization policies in Malaysia, Philippines, Thailand, and Vietnam. Most of these countries do not include meningococcal immunization in their routine vaccination programs, except for high-risk groups such as immunocompromised people and pilgrims. It is difficult to estimate the epidemiology of IMD in the highly diverse Asia-Pacific region, but available evidence indicate serogroup B is increasingly dominant. Disease surveillance systems differ by country. IMD is not a notifiable disease in some of them. Without an adequate surveillance system in the region, the risk and the burden of IMD might well be underestimated. With the availability of new combined meningococcal vaccines and the World Health Organization roadmap to defeat bacterial meningitis by 2030, a better understanding of the epidemiology of IMD in the Asia-Pacific region is needed.
- 20 May 2018
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 36 (15_suppl) , TPS9606
Multicenter phase 2 study to identify the optimal neo-adjuvant combination scheme of ipilimumab (IPI) and nivolumab (NIVO) (OpACIN-neo).
TPS9606Background: The outcome of high risk stage III melanoma patients (pts) is poor, with a 5 year overall survival (OS) rate of < 50%. Adjuvant (adj) high dose IPI significantly improves 5 year progression free survival (PFS) and OS and adj NIVO improves the median PFS even more. In stage IV pts, the combination of IPI and NIVO improves response rates (RR) and PFS compared to monotherapy, but at cost of higher toxicity. Neo-adjuvant (neoadj) treatment may be a favorable approach as immune checkpoint inhibition (ICI) is of greatest value at the moment of TCR triggering and therefore dependent on the amount of antigen. The phase Ib OpACIN study compared neoadj versus adj IPI plus NIVO. The pathological RR (pRR) was 80% in the neoadj arm, and to date after a median follow-up of 24 months, none of the responders has relapsed, while 4/10 pts have relapsed in the adj arm. Moreover, pts in the neoadj arm expanded more tumor-resident TCR clones than adj treated pts. Neoadj IPI+NIVO was feasible, but toxicity w...
- 20 May 2018
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 36 (15_suppl) , TPS9606
Multicenter phase 2 study to identify the optimal neo-adjuvant combination scheme of ipilimumab (IPI) and nivolumab (NIVO) (OpACIN-neo).
TPS9606Background: The outcome of high risk stage III melanoma patients (pts) is poor, with a 5 year overall survival (OS) rate of < 50%. Adjuvant (adj) high dose IPI significantly improves 5 year progression free survival (PFS) and OS and adj NIVO improves the median PFS even more. In stage IV pts, the combination of IPI and NIVO improves response rates (RR) and PFS compared to monotherapy, but at cost of higher toxicity. Neo-adjuvant (neoadj) treatment may be a favorable approach as immune checkpoint inhibition (ICI) is of greatest value at the moment of TCR triggering and therefore dependent on the amount of antigen. The phase Ib OpACIN study compared neoadj versus adj IPI plus NIVO. The pathological RR (pRR) was 80% in the neoadj arm, and to date after a median follow-up of 24 months, none of the responders has relapsed, while 4/10 pts have relapsed in the adj arm. Moreover, pts in the neoadj arm expanded more tumor-resident TCR clones than adj treated pts. Neoadj IPI+NIVO was feasible, but toxicity w...
- 1 October 2010
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 19 (10_Supplem) , B9
Abstract B9: A health disparities and clinical trials advocacy partnership to reduce colorectal cancer among Pacific Islanders in Southern California
Introduction: Pacific Islanders (PIs) are indigenous people from the Pacific who experience enormous cancer disparities in colorectal cancer (CRC) in Southern California, with incidence rates of 55/100,000 among PI males and 60/100,000 PI females, compared to only 40/100,000 among non-Hispanic white (NHW) males and 50/100,000 NHW females. Yet no programs outside of Hawai'i exist to assist PIs with accessing early CRC detection, diagnosis and treatment services. Methods: Patient navigation offers support and guidance to underserved populations, and in 2010 a NCI Community Cancer Center Program hospital (SJO: St. Joseph Hospital of Orange) and a Community Network Program (WINCART: Weaving an Islander Network for Cancer Awareness, Research and Training) instituted a community-based participatory research (CBPR) partnership for Chamorros, Marshallese, and Samoans in Orange County, California. The unique CBPR navigation effort involves three bilingual/bicultural PI health educators (at three WINCART affiliated community-based organizations) and a PI lay navigator (at SJO) to (1) effectively navigate PI men and women to a medical home in order to participate in CRC screening; (2) assisting patients with positive or suspicious findings to access additional diagnostic services, treatment and clinical trials advocacy; and (3) to ensure patient receives appropriate re-screening and diagnostics ideally in a St. Joseph Hospital community based medical home. Results: Preliminary activities have included development of clinical-community protocols for enrolling and tracking patients from screening through treatment, clinical trials education in a colorectal prevention trial as applicable and development and translation of culturally tailored CRC educational materials (including a flipchart, bookmark, and resource list) into the three PI languages. These materials and protocols have been pre-tested with PI adults age 50+ years, and are being implemented to assess improvements in regular screenings/re-screenings (when needed), diagnosis, and support services that a patient or family may need to ensure completion of treatment plans, with comprehensive data on navigated patients to be entered into SJO's existing navigator database. Conclusions: This is the first PI-specific CBPR navigation program in the continental U.S. and is based upon a partnership between two disparity-oriented institutions/programs (SJO and WINCART) to address the many critical factors (including mitigating the inability to pay for services, or to qualify/pay for healthcare insurance and clinical trials education) related to accessing culturally competent cancer care for PIs. Our CBPR navigation effort holds the potential to become a model for other clinical-community partnerships that aim to expand cancer services to small, ethnically distinct populations in the U.S. Citation Information: Cancer Epidemiol Biomarkers Prev 2010;19(10 Suppl):B9.
- 1 October 2010
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 19 (10_Supplem) , B9
Abstract B9: A health disparities and clinical trials advocacy partnership to reduce colorectal cancer among Pacific Islanders in Southern California
Introduction: Pacific Islanders (PIs) are indigenous people from the Pacific who experience enormous cancer disparities in colorectal cancer (CRC) in Southern California, with incidence rates of 55/100,000 among PI males and 60/100,000 PI females, compared to only 40/100,000 among non-Hispanic white (NHW) males and 50/100,000 NHW females. Yet no programs outside of Hawai'i exist to assist PIs with accessing early CRC detection, diagnosis and treatment services. Methods: Patient navigation offers support and guidance to underserved populations, and in 2010 a NCI Community Cancer Center Program hospital (SJO: St. Joseph Hospital of Orange) and a Community Network Program (WINCART: Weaving an Islander Network for Cancer Awareness, Research and Training) instituted a community-based participatory research (CBPR) partnership for Chamorros, Marshallese, and Samoans in Orange County, California. The unique CBPR navigation effort involves three bilingual/bicultural PI health educators (at three WINCART affiliated community-based organizations) and a PI lay navigator (at SJO) to (1) effectively navigate PI men and women to a medical home in order to participate in CRC screening; (2) assisting patients with positive or suspicious findings to access additional diagnostic services, treatment and clinical trials advocacy; and (3) to ensure patient receives appropriate re-screening and diagnostics ideally in a St. Joseph Hospital community based medical home. Results: Preliminary activities have included development of clinical-community protocols for enrolling and tracking patients from screening through treatment, clinical trials education in a colorectal prevention trial as applicable and development and translation of culturally tailored CRC educational materials (including a flipchart, bookmark, and resource list) into the three PI languages. These materials and protocols have been pre-tested with PI adults age 50+ years, and are being implemented to assess improvements in regular screenings/re-screenings (when needed), diagnosis, and support services that a patient or family may need to ensure completion of treatment plans, with comprehensive data on navigated patients to be entered into SJO's existing navigator database. Conclusions: This is the first PI-specific CBPR navigation program in the continental U.S. and is based upon a partnership between two disparity-oriented institutions/programs (SJO and WINCART) to address the many critical factors (including mitigating the inability to pay for services, or to qualify/pay for healthcare insurance and clinical trials education) related to accessing culturally competent cancer care for PIs. Our CBPR navigation effort holds the potential to become a model for other clinical-community partnerships that aim to expand cancer services to small, ethnically distinct populations in the U.S. Citation Information: Cancer Epidemiol Biomarkers Prev 2010;19(10 Suppl):B9.